CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | pioglitazone |
|
Accession: | CHEBI:8228
|
browse the term
|
Definition: | A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. |
Synonyms: | exact_synonym: | 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione |
| related_synonym: | (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; Formula=C19H20N2O3S; InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23); InChIKey=HYAFETHFCAUJAY-UHFFFAOYSA-N; SMILES=CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1; pioglitazona; pioglitazonum |
| xref: | CAS:111025-46-8; Chemspider:4663; DrugBank:DB01132; Drug_Central:2179; HMDB:HMDB0015264; KEGG:C07675; KEGG:D08378; LINCS:LSM-1592 |
| xref_mesh: | MESH:C060836 |
| xref: | PMID:12879407; PMID:14522601; PMID:17628757; PMID:18215232; PMID:20797618; PMID:27842070; PMID:33798599; PMID:33864097; PMID:33983968; PMID:33995271; PMID:34006325; PMID:34009030; Patent:EP193256; Patent:US4687777; Reaxys:3595485; Wikipedia:Pioglitazone |
|
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABAT mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
affects expression increases expression |
ISO |
pioglitazone affects the expression of ABCA1 protein pioglitazone results in increased expression of ABCA1 mRNA; pioglitazone results in increased expression of ABCA1 protein |
CTD |
PMID:15381068 PMID:17961437 PMID:19201410 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca4 |
ATP binding cassette subfamily A member 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABCA4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:210,164,813...210,302,069
Ensembl chr 2:210,164,813...210,302,069
|
|
G |
Abca6 |
ATP binding cassette subfamily A member 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABCA6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:95,142,805...95,212,087
Ensembl chr10:95,142,966...95,211,530
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABCA8B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
pioglitazone results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 PMID:22646477 PMID:23956101 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Pioglitazone results in increased expression of ABCB1 mRNA |
CTD |
PMID:31233785 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABCC9 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABI3BP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929
|
|
G |
Ablim2 |
actin binding LIM protein family, member 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABLIM2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:74,865,409...74,990,334
Ensembl chr14:74,866,281...74,990,334
|
|
G |
Abra |
actin-binding Rho activating protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABRA mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:72,970,187...72,974,255
Ensembl chr 7:72,970,186...72,974,255
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
pioglitazone results in decreased expression of ACAT1 mRNA |
CTD |
PMID:15381068 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of ACAT2 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [Streptozocin results in increased expression of ACE mRNA]; pioglitazone inhibits the reaction [Streptozocin results in increased expression of ACE protein] |
CTD |
PMID:16979161 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression increases secretion |
EXP |
Pioglitazone results in increased expression of ACE2 protein Pioglitazone results in increased secretion of ACE2 protein |
CTD |
PMID:24114819 PMID:24558317 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of ACOD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
decreases activity |
EXP |
Pioglitazone results in decreased activity of ACSL4 protein |
CTD |
PMID:11319222 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ACTA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP ISO |
pioglitazone affects the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] pioglitazone inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of ACTA2 mRNA]; pioglitazone inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] Pioglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:15052691 PMID:16484506 PMID:18513333 PMID:32613381 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ACTC1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:100,811,987...100,817,523
Ensembl chr 3:100,811,987...100,817,523
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ACTG2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465
|
|
G |
Actn2 |
actinin alpha 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ACTN2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622
|
|
G |
Adam23 |
ADAM metallopeptidase domain 23 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADAM23 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:64,862,649...65,009,718
Ensembl chr 9:64,862,878...65,006,515
|
|
G |
Adam5 |
ADAM metallopeptidase domain 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADAM5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:67,223,095...67,298,733
Ensembl chr16:67,223,143...67,298,737
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADAM9 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917
|
|
G |
Adcy5 |
adenylate cyclase 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADCY5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADCYAP1R1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adhfe1 |
alcohol dehydrogenase, iron containing, 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADHFE1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:9,705,966...9,732,580
Ensembl chr 5:9,705,970...9,732,517
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases expression decreases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone results in increased expression of ADIPOQ mRNA]; [N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of ADIPOQ mRNA; [Sodium Glutamate co-treated with Pioglitazone] results in increased expression of ADIPOQ protein; Pioglitazone promotes the reaction [Palmitates results in increased secretion of ADIPOQ protein]; PPARG protein affects the reaction [Pioglitazone results in increased expression of ADIPOQ mRNA] pioglitazone results in increased expression of ADIPOQ mRNA; pioglitazone results in increased expression of ADIPOQ protein Pioglitazone inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein]; Pioglitazone inhibits the reaction [Fructose results in decreased secretion of ADIPOQ protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; octocrylene inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; Pioglitazone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; T 0070907 inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]] Pioglitazone results in decreased expression of ADIPOQ protein |
CTD |
PMID:12927809 PMID:18303122 PMID:18513333 PMID:18815186 PMID:19048458 PMID:24622831 PMID:25679220 PMID:27918843 PMID:27935865 PMID:31016361 PMID:32407875 PMID:34864131 More...
|
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm |
adrenomedullin |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADM mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADORA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Agbl1 |
AGBL carboxypeptidase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AGBL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:130,043,914...130,950,739
Ensembl chr 1:130,043,970...130,951,638
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
Pioglitazone inhibits the reaction [Fructose results in increased expression of AGER protein] |
CTD |
PMID:25679220 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 mRNA]; pioglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 protein] |
CTD |
PMID:25874449 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AGTR1A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
ISO |
[ANGPT2 protein binds to and results in increased activity of AGTR2 protein] promotes the reaction [pioglitazone binds to and results in increased activity of PPARG protein]; [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AGTR2 mRNA |
CTD |
PMID:15992368 PMID:27935865 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Aifm3 |
AIF family member 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AIFM3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:83,504,859...83,523,630
Ensembl chr11:83,504,861...83,521,248
|
|
G |
Ajuba |
ajuba LIM protein |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AJUBA mRNA |
CTD |
PMID:20847119 |
|
NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Pioglitazone inhibits the reaction [streptozocin decreases phosphorylation of Akt1 protein in the liver] |
RGD |
PMID:29379801 |
RGD:408346751 |
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpk3 |
alpha-kinase 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ALPK3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:135,014,455...135,062,294
Ensembl chr 1:135,014,499...135,062,302
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AMIGO2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Amotl2 |
angiomotin like 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AMOTL2 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
|
|
G |
Ampd1 |
adenosine monophosphate deaminase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AMPD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:190,598,707...190,619,938
Ensembl chr 2:190,598,700...190,619,938
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
[ANGPT2 protein binds to and results in increased activity of AGTR2 protein] promotes the reaction [pioglitazone binds to and results in increased activity of PPARG protein] |
CTD |
PMID:15992368 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Angptl2 |
angiopoietin-like 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANGPTL2 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANGPTL2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
Pioglitazone results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ank1 |
ankyrin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ANK1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:68,876,294...69,054,963
Ensembl chr16:68,877,504...69,054,759
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr16:46,268,933...46,271,971
Ensembl chr16:46,268,443...46,271,963
|
|
G |
Ankrd63 |
ankyrin repeat domain 63 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ANKRD63 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:105,675,148...105,679,970
Ensembl chr 3:105,663,638...105,682,404
|
|
G |
Ano5 |
anoctamin 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ANO5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:101,086,490...101,187,547
Ensembl chr 1:101,087,341...101,187,555
|
|
G |
Aoc3 |
amine oxidase, copper containing 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AOC3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:86,272,757...86,280,702
|
|
G |
Ap1s2 |
adaptor related protein complex 1 subunit sigma 2 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of AP1S2 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr X:30,572,746...30,598,961
Ensembl chr X:30,572,751...30,597,262
|
|
G |
Apc2 |
APC regulator of WNT signaling pathway 2 |
increases expression |
ISO |
pioglitazone results in increased expression of APC2 mRNA |
CTD |
PMID:21347706 |
|
NCBI chr 7:9,392,336...9,414,364
Ensembl chr 7:9,392,336...9,414,310
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
ISO |
pioglitazone results in decreased expression of APOB protein |
CTD |
PMID:16324916 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc1 |
apolipoprotein C1 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in increased expression of APOC1 protein |
CTD |
PMID:16324916 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC2 protein [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of APOC2 mRNA |
CTD |
PMID:16324916 PMID:27935865 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apoc3 |
apolipoprotein C3 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein |
CTD |
PMID:16324916 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
App |
amyloid beta precursor protein |
decreases expression multiple interactions |
ISO |
pioglitazone results in decreased expression of APP protein mutant form pioglitazone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased metabolism of and results in increased secretion of APP protein alternative form]; pioglitazone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased metabolism of and results in increased secretion of APP protein alternative form] |
CTD |
PMID:14586007 PMID:15817521 PMID:16407166 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp7 |
aquaporin 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AQP7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AR mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Areg |
amphiregulin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of AREG mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Armcx2 |
armadillo repeat containing, X-linked 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ARMCX2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:97,980,662...97,985,523
Ensembl chr X:97,980,660...97,985,552
|
|
G |
Art1 |
ADP-ribosyltransferase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ART1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:156,478,096...156,487,172
Ensembl chr 1:156,482,621...156,487,172
|
|
G |
Asb10 |
ankyrin repeat and SOCS box-containing 10 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ASB10 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:10,630,318...10,644,270
Ensembl chr 4:10,630,448...10,639,060
|
|
G |
Asb14 |
ankyrin repeat and SOCS box-containing 14 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ASB14 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:2,095,567...2,123,259
Ensembl chr16:2,095,644...2,115,135
|
|
G |
Asb5 |
ankyrin repeat and SOCS box-containing 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ASB5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:37,237,869...37,305,207
Ensembl chr16:37,235,405...37,278,109
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ATF3 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ATP2A1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
pioglitazone results in decreased expression of ATP5F1B mRNA |
CTD |
PMID:20860658 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AVPR1A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
B4galnt2 |
beta-1,4-N-acetyl-galactosaminyl transferase 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of B4GALNT2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:80,801,594...80,828,005
Ensembl chr10:80,802,941...80,857,700
|
|
G |
B4galnt3 |
beta-1,4-N-acetyl-galactosaminyl transferase 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of B4GALNT3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:153,409,019...153,509,019
Ensembl chr 4:153,409,004...153,509,321
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions decreases expression decreases activity |
ISO |
pioglitazone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased expression of and results in increased activity of BACE1 protein] pioglitazone results in decreased expression of BACE1 mRNA pioglitazone results in decreased activity of BACE1 protein pioglitazone results in decreased expression of BACE1 mRNA; pioglitazone results in decreased expression of BACE1 protein |
CTD |
PMID:14586007 PMID:15817521 PMID:16407166 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA]; Pioglitazone inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA] |
CTD |
PMID:30130594 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BCHE mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl11a |
BCL11 transcription factor A |
decreases expression |
ISO |
Pioglitazone results in decreased expression of BCL11A mRNA |
CTD |
PMID:30031879 |
|
NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
[naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA]; Pioglitazone inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA] |
CTD |
PMID:30130594 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
Pioglitazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of BDNF protein] |
CTD |
PMID:32735850 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bend5 |
BEN domain containing 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BEND5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:126,290,648...126,336,662
Ensembl chr 5:125,254,956...126,534,367
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA] |
CTD |
PMID:32473317 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of BIRC3 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Pioglitazone results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bpifa5 |
BPI fold containing family A, member 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of BPIFA5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:142,646,103...142,652,884
Ensembl chr 3:142,646,103...142,652,883
|
|
G |
Bpifb1 |
BPI fold containing family B, member 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BPIFB1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:142,672,995...142,706,258
Ensembl chr 3:142,672,995...142,706,256
|
|
G |
Bsg |
basigin |
multiple interactions decreases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]]; pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein] pioglitazone results in decreased expression of BSG protein |
CTD |
PMID:16860414 PMID:17007354 PMID:17055343 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Btn2a2 |
butyrophilin, subfamily 2, member A2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BTN2A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:41,620,807...41,632,621
Ensembl chr17:41,620,839...41,632,618
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of BZW1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BZW1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 9:59,930,672...59,944,468
Ensembl chr 9:59,930,744...59,944,430
|
|
G |
C1qtnf7 |
C1q and TNF related 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of C1QTNF7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:67,467,888...67,580,477
Ensembl chr14:67,468,014...67,580,410
|
|
G |
C2h1orf54 |
similar to human chromosome 1 open reading frame 54 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of C1ORF54 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 2:183,424,989...183,434,713
Ensembl chr 2:183,424,984...183,435,089
|
|
G |
C4a |
complement C4A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of C4A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:4,005,731...4,020,083
Ensembl chr20:4,005,731...4,020,080
|
|
G |
C5ar1 |
complement C5a receptor 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of C5AR1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Cabcoco1 |
ciliary associated calcium binding coiled-coil 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CABCOCO1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:20,058,492...20,167,973
Ensembl chr20:20,058,454...20,167,725
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA1C mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Cacna1s |
calcium voltage-gated channel subunit alpha1 S |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA1S mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318
|
|
G |
Cacna2d3 |
calcium voltage-gated channel auxiliary subunit alpha2delta 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA2D3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:4,098,439...4,912,498
Ensembl chr16:4,098,445...4,912,351
|
|
G |
Cadm2 |
cell adhesion molecule 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CADM2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:4,548,367...5,525,420
Ensembl chr11:4,555,159...5,525,400
|
|
G |
Calhm5 |
calcium homeostasis modulator family member 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CALHM5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:26,066,270...26,072,348
Ensembl chr20:26,066,242...26,072,272
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CAR3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
pioglitazone inhibits the reaction [Galactose results in increased activity of CASP3 protein] [Fenofibrate co-treated with Pioglitazone] inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA]; Pioglitazone inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Pioglitazone inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA] |
CTD |
PMID:23795773 PMID:30130594 PMID:36988379 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casq1 |
calsequestrin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CASQ1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:84,670,648...84,680,339
Ensembl chr13:84,670,649...84,680,339
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Pioglitazone inhibits the reaction [Quinolinic Acid results in decreased activity of CAT protein]]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [Quinolinic Acid results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [Streptozocin results in decreased activity of CAT protein] Pioglitazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased activity of CAT protein] |
CTD |
PMID:20450929 PMID:27350165 PMID:29233026 PMID:29247773 PMID:32735850 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
affects expression |
ISO |
pioglitazone affects the expression of CAV1 protein |
CTD |
PMID:17961437 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cav3 |
caveolin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CAV3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:145,582,168...145,598,142
Ensembl chr 4:145,582,060...145,598,137
|
|
G |
Ccdc159 |
coiled-coil domain containing 159 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CCDC159 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:20,457,905...20,467,232
Ensembl chr 8:20,457,909...20,466,562
|
|
G |
Ccdc85a |
coiled-coil domain containing 85A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CCDC85A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:102,126,574...102,359,207
Ensembl chr14:102,129,029...102,359,058
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of CCL11 protein] |
CTD |
PMID:17015710 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCL2 mRNA; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein] [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CCL2 mRNA |
CTD |
PMID:20847119 PMID:27935865 PMID:32613381 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions decreases expression |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CCL3 mRNA Pioglitazone results in decreased expression of CCL3 mRNA |
CTD |
PMID:27935865 PMID:30031879 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions decreases response to substance |
ISO |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of CCL5 protein] pioglitazone results in decreased susceptibility to CCL5 protein |
CTD |
PMID:17015710 PMID:18158351 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CCL7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO EXP |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA] Pioglitazone affects the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA] |
CTD |
PMID:16484506 PMID:20847119 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna1 |
cyclin A1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CCNA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CCNA2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CCNB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
pioglitazone results in decreased expression of CCND1 mRNA; pioglitazone results in decreased expression of CCND1 protein Pioglitazone results in decreased expression of CCND1 mRNA pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of CCND1 protein] |
CTD |
PMID:17077279 PMID:26643070 PMID:30031879 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CCND3 protein |
CTD |
PMID:15729575 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CCNE1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccno |
cyclin O |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CCNO mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:44,630,873...44,633,912
Ensembl chr 2:44,626,369...44,633,914
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO EXP |
Pioglitazone results in increased expression of CD36 mRNA; Pioglitazone results in increased expression of CD36 protein pioglitazone results in increased expression of CD36 mRNA [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CD36 mRNA Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; PPARG protein affects the reaction [Pioglitazone results in increased expression of CD36 protein] |
CTD |
PMID:15381068 PMID:16484506 PMID:17143554 PMID:19048458 PMID:20723549 PMID:26643070 PMID:28263783 PMID:30031879 PMID:32613381 More...
|
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd84 |
CD84 molecule |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CD84 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr13:84,327,580...84,367,153
Ensembl chr13:84,327,553...84,362,076
|
|
G |
Cdc20b |
cell division cycle 20B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CDC20B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:44,688,349...44,738,056
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CDC42 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CDK2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkl1 |
cyclin dependent kinase like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CDKL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 6:88,224,154...88,273,434
Ensembl chr 6:88,224,143...88,270,276
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression |
EXP ISO |
pioglitazone inhibits the reaction [2-Acetylaminofluorene inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN1A protein]]; pioglitazone promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN1A protein] pioglitazone results in decreased expression of CDKN1A protein Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]; Pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of CDKN1A protein]; Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]; Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]] |
CTD |
PMID:15729575 PMID:17582756 PMID:26643070 PMID:29734669 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
EXP ISO |
pioglitazone inhibits the reaction [2-Acetylaminofluorene promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN1B protein]]; pioglitazone promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN1B protein] pioglitazone results in increased expression of CDKN1B protein pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased degradation of CDKN1B protein]; PRKAA1 protein affects the reaction [pioglitazone results in increased expression of CDKN1B protein] |
CTD |
PMID:17582756 PMID:26643070 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1C mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
pioglitazone results in increased expression of CEBPA mRNA |
CTD |
PMID:28242381 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cemip |
cell migration inducing hyaluronidase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CEMIP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
pioglitazone results in increased expression of CES1 mRNA |
CTD |
PMID:15381068 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CFD mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Chchd6 |
coiled-coil-helix-coiled-coil-helix domain containing 6 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CHCHD6 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:121,803,501...122,024,209
Ensembl chr 4:121,792,717...122,024,216
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in increased expression of CHI3L1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chit1 |
chitinase 1 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CHIT1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr13:45,565,841...45,613,593
Ensembl chr13:45,593,845...45,613,592
|
|
G |
Chp2 |
calcineurin-like EF hand protein 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHP2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:176,757,945...176,772,443
Ensembl chr 1:176,757,876...176,772,139
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHRM1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHRM2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrna1 |
cholinergic receptor nicotinic alpha 1 subunit |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHRNA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:58,454,763...58,469,832
Ensembl chr 3:58,454,744...58,469,840
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHRNE mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,331,212...55,335,530
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of CHUK mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CIDEC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CKM mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Ckmt2 |
creatine kinase, mitochondrial 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CKMT2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:23,079,918...23,110,518
Ensembl chr 2:23,079,918...23,110,430
|
|
G |
Clec14a |
C-type lectin domain containing 14A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CLEC14A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 6:75,881,470...75,884,612
Ensembl chr 6:75,881,473...75,884,612
|
|
G |
Clec1a |
C-type lectin domain family 1, member A |
increases expression |
ISO |
Pioglitazone results in increased expression of CLEC1A mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:162,875,360...162,902,571
Ensembl chr 4:162,877,346...162,901,247
|
|
G |
Clec4a3 |
C-type lectin domain family 4, member A3 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CLEC4A mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:156,214,030...156,224,818
Ensembl chr 4:156,214,718...156,224,817
|
|
G |
Clec4d |
C-type lectin domain family 4, member D |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CLEC4D mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:156,589,591...156,599,279
Ensembl chr 4:156,589,792...156,598,848
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CLEC4E mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:156,606,927...156,612,911
Ensembl chr 4:156,607,614...156,612,767
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cmya5 |
cardiomyopathy associated 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CMYA5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:24,279,520...24,378,253
Ensembl chr 2:24,279,528...24,378,364
|
|
G |
Cnga3 |
cyclic nucleotide gated channel subunit alpha 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CNGA3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:39,447,534...39,494,044
Ensembl chr 9:39,448,034...39,493,183
|
|
G |
Cnn1 |
calponin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CNN1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cnrip1 |
cannabinoid receptor interacting protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CNRIP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:91,462,877...91,492,739
Ensembl chr14:91,462,647...91,492,735
|
|
G |
Cntd1 |
cyclin N-terminal domain containing 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CNTD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:86,221,430...86,231,812
|
|
G |
Cog8 |
component of oligomeric golgi complex 8 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of COG8 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr19:34,951,625...34,962,377
Ensembl chr19:34,951,627...34,962,397
|
|
G |
Col6a5 |
collagen type VI alpha 5 chain |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of COL6A5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:106,483,806...106,584,114
Ensembl chr 8:106,483,799...106,584,113
|
|
G |
Coro6 |
coronin 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CORO6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:62,311,552...62,319,659
Ensembl chr10:62,311,660...62,319,659
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of COX6A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression |
ISO |
pioglitazone results in increased expression of CPT1B mRNA |
CTD |
PMID:20723549 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpxm1 |
carboxypeptidase X (M14 family), member 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CPXM1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:117,588,532...117,595,330
Ensembl chr 3:117,588,532...117,595,330
|
|
G |
Cpz |
carboxypeptidase Z |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CPZ mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:75,223,692...75,246,946
Ensembl chr14:75,223,605...75,246,945
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Pioglitazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of CREB1 protein] |
CTD |
PMID:32735850 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
increases expression |
ISO |
Pioglitazone results in increased expression of CRH mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CRHR2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G |
Crispld1 |
cysteine-rich secretory protein LCCL domain containing 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CRISPLD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:1,267,347...1,314,926
Ensembl chr 5:1,274,647...1,314,926
|
|
G |
Crp |
C-reactive protein |
affects expression decreases expression |
EXP ISO |
pioglitazone affects the expression of CRP protein Pioglitazone results in decreased expression of CRP protein |
CTD |
PMID:28705172 PMID:28744220 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CRYAB mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CRYAB mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Crym |
crystallin, mu |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CRYM mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:174,560,423...174,575,660
Ensembl chr 1:174,560,416...174,575,633
|
|
G |
Csn1s1 |
casein alpha s1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CSN1S1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:20,343,620...20,359,614
Ensembl chr14:20,343,619...20,359,614
|
|
G |
Csrp3 |
cysteine and glycine rich protein 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CSRP3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:98,528,067...98,546,647
Ensembl chr 1:98,528,068...98,546,653
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CTLA4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CTNNB1 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases response to substance multiple interactions |
ISO |
pioglitazone results in decreased susceptibility to CXCL12 protein pioglitazone inhibits the reaction [CXCL12 protein affects the localization of ICAM3 protein] [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CXCL12 mRNA |
CTD |
PMID:18158351 PMID:27935865 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CXCL2 mRNA; [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA |
CTD |
PMID:27935865 PMID:28263783 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CXCL3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CXCR3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CXCR4 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression affects activity |
ISO |
pioglitazone results in decreased expression of CYBA mRNA pioglitazone affects the activity of CYBA protein |
CTD |
PMID:11172467 PMID:21962020 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions decreases activity decreases expression |
ISO |
pioglitazone inhibits the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in increased activity of CYP17A1 protein]; pioglitazone inhibits the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in increased expression of CYP17A1 mRNA] pioglitazone results in decreased activity of CYP17A1 protein pioglitazone results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:15072549 PMID:17138841 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP |
pioglitazone results in increased expression of CYP2B1 mRNA |
CTD |
PMID:16597547 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
pioglitazone results in increased expression of CYP2B6 protein Pioglitazone results in increased expression of CYP2B10 mRNA |
CTD |
PMID:12642470 PMID:28541575 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases expression |
ISO |
Pioglitazone results in increased expression of CYP2C55 mRNA |
CTD |
PMID:28541575 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
multiple interactions affects metabolic processing decreases activity increases expression |
ISO |
Gemfibrozil inhibits the reaction [CYP2C8 protein affects the metabolism of pioglitazone] pioglitazone results in decreased activity of CYP2C8 protein Pioglitazone results in increased expression of CYP2C8 mRNA |
CTD |
PMID:12642470 PMID:15900286 PMID:31233785 |
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2g1 |
cytochrome P450, family 2, subfamily g, polypeptide 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CYP2G1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:82,145,635...82,156,862
Ensembl chr 1:82,145,073...82,156,828
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression affects metabolic processing decreases activity |
EXP ISO |
pioglitazone inhibits the reaction [Endotoxins results in decreased expression of CYP3A2 protein] [Pioglitazone results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Pioglitazone results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; Pioglitazone results in increased expression of and results in increased activity of CYP3A4 protein Pioglitazone results in increased expression of CYP3A4 mRNA; Pioglitazone results in increased expression of CYP3A4 protein CYP3A4 protein affects the metabolism of Pioglitazone Pioglitazone results in decreased activity of CYP3A4 protein |
CTD |
PMID:12642470 PMID:15364003 PMID:15860655 PMID:15900286 PMID:16837568 PMID:22524704 PMID:31233785 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Pioglitazone results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:16597547 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
pioglitazone promotes the reaction [U 0126 results in increased expression of CYP7A1 mRNA]; U 0126 promotes the reaction [pioglitazone results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:22593575 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dcaf12l1 |
DDB1 and CUL4 associated factor 12-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DCAF12L1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:123,695,286...123,698,905
Ensembl chr X:123,695,286...123,698,905
|
|
G |
Dcx |
doublecortin |
multiple interactions |
ISO |
Pioglitazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of DCX protein] |
CTD |
PMID:32735850 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DDAH1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions increases expression |
ISO |
[Metformin co-treated with Pioglitazone] results in increased expression of DDIT4 mRNA Pioglitazone results in increased expression of DDIT4 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
multiple interactions increases expression |
ISO |
[Metformin co-treated with Pioglitazone] results in increased expression of DDIT4L mRNA Pioglitazone results in increased expression of DDIT4L mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DEPP1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DEPP1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of DEPTOR mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Derl3 |
derlin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DERL3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Des |
desmin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DES mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Deup1 |
deuterosome assembly protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DEUP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:12,380,300...12,442,649
Ensembl chr 8:12,380,302...12,442,199
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression |
ISO |
pioglitazone results in increased expression of DGAT1 mRNA |
CTD |
PMID:20723549 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
increases expression |
ISO |
pioglitazone results in increased expression of DGAT2 mRNA |
CTD |
PMID:20723549 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Dhrs7c |
dehydrogenase/reductase 7C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DHRS7C mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:52,495,262...52,513,338
Ensembl chr10:52,495,262...52,513,338
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
increases activity multiple interactions increases expression |
ISO |
pioglitazone results in increased activity of DIO2 protein PPARG protein promotes the reaction [pioglitazone results in increased activity of DIO2 protein] pioglitazone results in increased expression of DIO2 mRNA |
CTD |
PMID:19036883 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
pioglitazone results in decreased activity of DIO3 protein |
CTD |
PMID:19036883 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DLG1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Dmbt1 |
deleted in malignant brain tumors 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DMBT1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:185,617,469...185,696,476
Ensembl chr 1:185,617,294...185,696,478
|
|
G |
Dnaaf2 |
dynein, axonemal, assembly factor 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DNAAF2 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of DNAAF2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 6:87,661,101...87,670,267
Ensembl chr 6:87,660,821...87,670,199
|
|
G |
Dnah8 |
dynein, axonemal, heavy chain 8 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DNAH8 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:8,692,939...8,946,780
Ensembl chr20:8,692,963...8,946,772
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DNER mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dpt |
dermatopontin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DPT mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:77,123,224...77,151,646
Ensembl chr13:77,123,115...77,151,639
|
|
G |
Dpy19l2 |
dpy-19 like 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DPY19L2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:23,062,592...23,181,817
Ensembl chr 8:23,063,115...23,181,798
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DRD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DUSP10 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp26 |
dual specificity phosphatase 26 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DUSP26 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:61,041,784...61,049,319
Ensembl chr16:61,041,792...61,049,051
|
|
G |
Eddm3b |
epididymal protein 3B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of EDDM3B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:24,343,992...24,346,759
Ensembl chr15:24,345,573...24,346,025
|
|
G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EEF1A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:168,265,893...168,275,071
Ensembl chr 3:168,195,357...168,275,071
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EGF mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egflam |
EGF-like, fibronectin type III and laminin G domains |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EGFLAM mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:56,301,945...56,476,665
Ensembl chr 2:56,302,566...56,476,298
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of EIF4E mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions decreases phosphorylation increases expression |
ISO |
pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of EIF4EBP1 protein] pioglitazone results in decreased phosphorylation of EIF4EBP1 protein Pioglitazone results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:26643070 PMID:32589349 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif4ebp2 |
eukaryotic translation initiation factor 4E binding protein 2 |
increases expression |
ISO |
Pioglitazone results in increased expression of EIF4EBP2 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr20:29,379,444...29,400,110
Ensembl chr20:29,382,668...29,399,946
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
increases expression |
ISO |
pioglitazone results in increased expression of EIF5A mRNA |
CTD |
PMID:21347706 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Elovl4 |
ELOVL fatty acid elongase 4 |
increases expression |
ISO |
Pioglitazone results in increased expression of ELOVL4 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 8:84,702,916...84,729,466
Ensembl chr 8:84,702,362...84,729,697
|
|
G |
Eno3 |
enolase 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ENO3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Epgn |
epithelial mitogen |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of EPGN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:17,076,774...17,084,806
Ensembl chr14:17,076,774...17,084,806
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EPHA3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900
|
|
G |
Epha5 |
EPH receptor A5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EPHA5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:23,653,393...24,020,129
Ensembl chr14:23,653,393...24,017,317
|
|
G |
Epyc |
epiphycan |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EPYC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:32,436,620...32,474,326
Ensembl chr 7:32,436,620...32,474,135
|
|
G |
Erbin |
erbb2 interacting protein |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ERBIN mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 2:34,926,962...35,028,440
Ensembl chr 2:34,928,863...35,027,852
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Pioglitazone results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of F10 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FABP3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with Tretinoin] results in increased expression of FABP4 mRNA Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA] pioglitazone results in increased expression of FABP4 mRNA Pioglitazone results in increased expression of FABP4 mRNA |
CTD |
PMID:9543393 PMID:12927809 PMID:15273253 PMID:16573735 PMID:17290005 PMID:19048458 PMID:30031879 PMID:32473317 More...
|
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fam13a |
family with sequence similarity 13, member A |
increases expression |
ISO |
Pioglitazone results in increased expression of FAM13A mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:88,056,521...88,155,782
Ensembl chr 4:88,058,403...88,155,860
|
|
G |
Fam171b |
family with sequence similarity 171, member B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FAM171B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127
|
|
G |
Fam184b |
family with sequence similarity 184, member B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FAM184B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:65,475,489...65,591,388
Ensembl chr14:65,475,489...65,591,388
|
|
G |
Fam210a |
family with sequence similarity 210, member A |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of FAM210A mRNA |
CTD |
PMID:20847119 |
|
NCBI chr18:61,846,447...61,886,123
Ensembl chr18:61,852,907...61,886,171
|
|
G |
Fam240b |
family with sequence similarity 240 member B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of FAM240B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:647,269...663,209
Ensembl chr17:657,303...663,206
|
|
G |
Fam47e |
family with sequence similarity 47, member E |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FAM47E mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:15,485,537...15,521,599
Ensembl chr14:15,485,127...15,521,775
|
|
G |
Fat4 |
FAT atypical cadherin 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FAT4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:121,927,266...122,056,700
Ensembl chr 2:121,927,942...122,056,707
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of FBLN1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbln7 |
fibulin 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBLN7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:116,111,581...116,145,839
Ensembl chr 3:116,111,677...116,147,983
|
|
G |
Fbxl16 |
F-box and leucine-rich repeat protein 16 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBXL16 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:14,829,453...14,841,739
Ensembl chr10:14,829,449...14,840,986
|
|
G |
Fbxo40 |
F-box protein 40 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBXO40 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:63,794,452...63,812,697
Ensembl chr11:63,794,624...63,812,697
|
|
G |
Fbxo43 |
F-box protein 43 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBXO43 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:67,333,161...67,346,751
Ensembl chr 7:67,333,162...67,346,751
|
|
G |
Fcmr |
Fc mu receptor |
increases expression |
ISO |
Pioglitazone results in increased expression of FCMR mRNA |
CTD |
PMID:30031879 |
|
NCBI chr13:42,337,363...42,351,706
Ensembl chr13:42,337,414...42,351,653
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression |
ISO |
pioglitazone results in increased expression of FGF21 mRNA |
CTD |
PMID:21720023 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FGF7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgl1 |
fibrinogen-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FGL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:51,120,652...51,150,907
Ensembl chr16:51,120,694...51,151,093
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of FHL1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Filip1 |
filamin A interacting protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FILIP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:80,761,283...80,956,556
Ensembl chr 8:80,764,604...80,922,549
|
|
G |
Fjx1 |
four-jointed box kinase 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of FJX1 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 3:88,774,220...88,776,321
Ensembl chr 3:88,774,220...88,776,321
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
increases expression |
ISO |
Pioglitazone results in increased expression of FKBP1A mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743
|
|
G |
Fkbp8 |
FKBP prolyl isomerase 8 |
increases expression |
ISO |
Pioglitazone results in increased expression of FKBP8 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr16:18,895,608...18,902,648
Ensembl chr16:18,893,576...18,902,612
|
|
G |
Flnc |
filamin C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FLNC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Fndc5 |
fibronectin type III domain containing 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FNDC5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
pioglitazone results in increased expression of FOS mRNA |
CTD |
PMID:11687581 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of FOSB mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of FOSL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxn4 |
forkhead box N4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FOXN4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:42,336,706...42,359,932
Ensembl chr12:42,340,323...42,359,921
|
|
G |
Fpr1 |
formyl peptide receptor 1 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of FPR1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559
|
|
G |
Frzb |
frizzled-related protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FRZB mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of FSCN1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Fsd2 |
fibronectin type III and SPRY domain containing 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FSD2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:135,484,002...135,522,517
Ensembl chr 1:135,489,266...135,522,472
|
|
G |
Fxyd1 |
FXYD domain-containing ion transport regulator 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FXYD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278
|
|
G |
Gabra3 |
gamma-aminobutyric acid type A receptor subunit alpha 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GABRA3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:150,244,745...150,501,566
Ensembl chr X:150,261,607...150,501,559
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GABRA4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
|
|
G |
Galnt16 |
polypeptide N-acetylgalactosaminyltransferase 16 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GALNT16 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:100,170,306...100,250,705
|
|
G |
Galnt17 |
polypeptide N-acetylgalactosaminyltransferase 17 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of GALNT17 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:25,323,230...25,781,897
Ensembl chr12:25,322,701...25,781,290
|
|
G |
Galnt9 |
polypeptide N-acetylgalactosaminyltransferase 9 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of GALNT9 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:46,050,395...46,128,626
Ensembl chr12:46,050,413...46,128,578
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of GDF15 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of GEM mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222
|
|
G |
Gemin4 |
gem (nuclear organelle) associated protein 4 |
multiple interactions |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of GEMIN4 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr10:61,062,420...61,073,529
Ensembl chr10:61,066,425...61,073,431 Ensembl chr10:61,066,425...61,073,431
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GFRA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Gh1 |
growth hormone 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of GH1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gimap4 |
GTPase, IMAP family member 4 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of GIMAP4 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:77,636,401...77,643,315
Ensembl chr 4:77,636,401...77,643,306
|
|
G |
Gldn |
gliomedin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GLDN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:54,679,015...54,723,198
Ensembl chr 8:54,679,119...54,723,196
|
|
G |
Gmnc |
geminin coiled-coil domain containing |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GMNC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:73,836,255...73,847,698
Ensembl chr11:73,814,533...73,847,328
|
|
G |
Gnat3 |
G protein subunit alpha transducin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GNAT3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:17,162,500...17,212,283
Ensembl chr 4:17,162,490...17,212,283
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [[Ethanol co-treated with Lipopolysaccharides] results in increased expression of GOT1 protein] |
CTD |
PMID:15318101 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Got1l1 |
glutamic-oxaloacetic transaminase 1-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GOT1L1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:64,860,308...64,873,656
Ensembl chr16:64,860,704...64,866,162
|
|
G |
Gp2 |
glycoprotein 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GP2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:173,797,057...173,812,619
Ensembl chr 1:173,797,057...173,812,619
|
|
G |
Gpihbp1 |
glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GPIHBP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:107,285,584...107,288,702
Ensembl chr 7:107,285,654...107,288,702
|
|
G |
Gpm6a |
glycoprotein m6a |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GPM6A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:36,641,282...36,973,377
Ensembl chr16:36,641,284...36,973,475
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of GPR183 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gpr84 |
G protein-coupled receptor 84 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of GPR84 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:134,443,904...134,446,173
Ensembl chr 7:134,443,936...134,446,178
|
|
G |
Gprasp2 |
G protein-coupled receptor associated sorting protein 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GPRASP2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:98,817,668...98,823,814
Ensembl chr X:98,817,593...98,824,402
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [[Ethanol co-treated with Lipopolysaccharides] results in increased expression of GPT protein]; pioglitazone inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased activity of GPT protein] |
CTD |
PMID:15318101 PMID:27350165 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Pioglitazone results in increased expression of GPX3 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Grm4 |
glutamate metabotropic receptor 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of GRM4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:5,484,172...5,572,821
Ensembl chr20:5,481,124...5,572,821
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases expression |
ISO |
Pioglitazone results in increased expression of GSK3B mRNA |
CTD |
PMID:32589349 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
[pioglitazone co-treated with alitretinoin] results in increased expression of GSTA2 protein |
CTD |
PMID:15150131 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [Diethylnitrosamine results in increased expression of GSTP1 protein] |
CTD |
PMID:15526359 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GSTT1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GUCY1A1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions |
EXP |
Pioglitazone inhibits the reaction [Fructose promotes the reaction [Glucose binds to HBB protein]] |
CTD |
PMID:25679220 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hecw1 |
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of HECW1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:50,671,239...51,084,536
Ensembl chr17:50,670,954...51,080,720
|
|
G |
Hhatl |
hedgehog acyltransferase-like |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of HHATL mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:121,447,001...121,454,070
Ensembl chr 8:121,447,002...121,454,001
|
|
G |
Hhip |
Hedgehog-interacting protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of HHIP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr19:27,863,684...27,952,528
Ensembl chr19:27,863,213...27,952,528
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression multiple interactions |
ISO |
Pioglitazone results in decreased expression of HIF1A mRNA [Metformin co-treated with Pioglitazone] results in decreased expression of HIF1A mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hif3a |
hypoxia inducible factor 3 subunit alpha |
decreases expression |
EXP |
pioglitazone results in decreased expression of HIF3A mRNA |
CTD |
PMID:22456468 |
|
NCBI chr 1:77,718,110...77,750,448
Ensembl chr 1:77,722,471...77,749,758
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of HILPDA mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of HILPDA mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557
|
|
G |
Hjv |
hemojuvelin BMP co-receptor |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of HJV mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:184,065,944...184,069,851
Ensembl chr 2:184,065,970...184,069,850
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression decreases expression |
ISO |
pioglitazone results in increased expression of HMGCR mRNA pioglitazone results in decreased expression of HMGCR mRNA |
CTD |
PMID:12044893 PMID:20503262 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
pioglitazone results in increased expression of HMGCS1 mRNA |
CTD |
PMID:12044893 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
pioglitazone results in increased expression of HMOX1 mRNA [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of HMOX1 mRNA]; Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA] |
CTD |
PMID:16597547 PMID:28263783 PMID:30965670 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of HNRNPDL mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of HNRNPDL mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
multiple interactions |
ISO |
[pioglitazone co-treated with NAD] binds to HPGD protein |
CTD |
PMID:25526675 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hpse2 |
heparanase 2 (inactive) |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of HPSE2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:241,582,904...242,284,348
Ensembl chr 1:241,583,187...242,246,118
|
|
G |
Hrc |
histidine rich calcium binding protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of HRC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:95,813,262...95,816,987
Ensembl chr 1:95,813,253...95,816,984
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
decreases expression decreases activity |
ISO |
pioglitazone results in decreased expression of HSD3B2 mRNA pioglitazone results in decreased activity of HSD3B2 protein |
CTD |
PMID:15072549 PMID:17138841 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hspa12b |
heat shock protein family A (Hsp70) member 12B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of HSPA12B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:118,346,372...118,364,374
Ensembl chr 3:118,346,354...118,364,737
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of HSPA1L mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of HSPA1L mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
|
|
G |
Hspb7 |
heat shock protein family B (small) member 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of HSPB7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:153,727,782...153,731,268
Ensembl chr 5:153,727,588...153,731,266
|
|
G |
Htr2b |
5-hydroxytryptamine receptor 2B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of HTR2B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of ICAM1 protein] |
CTD |
PMID:17015710 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
multiple interactions |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ID2 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ID2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased metabolism of and results in increased secretion of APP protein alternative form]; pioglitazone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased expression of and results in increased activity of BACE1 protein]; pioglitazone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased metabolism of and results in increased secretion of APP protein alternative form] |
CTD |
PMID:14586007 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression multiple interactions |
ISO |
Pioglitazone results in decreased expression of IGF1 mRNA [Metformin co-treated with Pioglitazone] results in decreased expression of IGF1 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igsf10 |
immunoglobulin superfamily, member 10 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of IGSF10 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:143,575,710...143,605,044
Ensembl chr 2:143,576,070...143,604,773
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
decreases expression |
ISO |
Pioglitazone results in decreased expression of IKBKB mRNA |
CTD |
PMID:32589349 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
EXP ISO |
Pioglitazone inhibits the reaction [propionic acid results in decreased expression of IL10 protein] Pioglitazone results in increased expression of IL10 protein |
CTD |
PMID:27918843 PMID:31348919 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of IL13 protein] |
CTD |
PMID:17015710 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA] |
CTD |
PMID:18660453 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Pioglitazone results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions affects expression increases expression |
ISO EXP |
Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Pioglitazone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased metabolism of and results in increased secretion of APP protein alternative form]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein] pioglitazone affects the expression of IL1B mRNA [pioglitazone co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA Pioglitazone results in increased expression of IL1B mRNA [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of IL1B mRNA]; Fenofibrate promotes the reaction [Pioglitazone inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]]; Pioglitazone inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; Pioglitazone inhibits the reaction [Fructose results in increased secretion of IL1B protein]; Pioglitazone inhibits the reaction [Quinolinic Acid results in increased expression of IL1B mRNA]; Pioglitazone promotes the reaction [Fenofibrate inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]] |
CTD |
PMID:14586007 PMID:25679220 PMID:28138970 PMID:30031879 PMID:30130594 PMID:32613381 PMID:32816093 PMID:36988379 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of IL23A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il24 |
interleukin 24 |
multiple interactions increases expression |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of IL24 mRNA Pioglitazone results in increased expression of IL24 mRNA |
CTD |
PMID:27935865 PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of IL4 protein] |
CTD |
PMID:17015710 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of IL5 protein] |
CTD |
PMID:17015710 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions affects expression increases expression |
ISO EXP |
[Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Sodium Glutamate co-treated with Pioglitazone] results in decreased expression of IL6 protein; Pioglitazone inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL6 mRNA]; Pioglitazone inhibits the reaction [Sodium Glutamate results in increased expression of IL6 mRNA]; Pioglitazone promotes the reaction [Plant Extracts results in increased expression of IL6 protein] pioglitazone affects the expression of IL6 protein [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of IL6 mRNA]; Pioglitazone inhibits the reaction [propionic acid results in increased expression of IL6 protein]; Pioglitazone inhibits the reaction [Quinolinic Acid results in increased expression of IL6 mRNA]; Pioglitazone inhibits the reaction [Streptozocin results in increased expression of IL6 protein] Pioglitazone results in increased expression of IL6 protein |
CTD |
PMID:18513333 PMID:27918843 PMID:28263783 PMID:28744220 PMID:29233026 PMID:30130594 PMID:31348919 PMID:37044004 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilk |
integrin-linked kinase |
decreases expression |
ISO |
Pioglitazone results in decreased expression of ILK mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G |
Inmt |
indolethylamine N-methyltransferase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of INMT mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:84,318,197...84,322,493
Ensembl chr 4:84,318,197...84,322,493
|
|
G |
Ins1 |
insulin 1 |
multiple interactions affects expression decreases secretion |
EXP ISO |
Pioglitazone inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of INS1 protein]; Pioglitazone inhibits the reaction [Streptozocin results in increased expression of INS1 protein] Pioglitazone promotes the reaction [INS1 protein results in increased uptake of Glucose] Pioglitazone affects the expression of INS1 protein Pioglitazone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] Pioglitazone results in decreased secretion of INS1 protein |
CTD |
PMID:14532171 PMID:19208898 PMID:27350165 PMID:28242381 PMID:29233026 PMID:32407875 PMID:37044004 More...
|
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; [Dexamethasone co-treated with INS protein co-treated with Pioglitazone] results in increased expression of PPARG protein; octocrylene inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; T 0070907 inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]] [Dexamethasone co-treated with INS protein co-treated with Pioglitazone] results in increased expression of PPARG protein; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA] |
CTD |
PMID:15273253 PMID:17290005 PMID:31016361 PMID:32473317 PMID:32613381 PMID:34864131 More...
|
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insyn2b |
inhibitory synaptic factor family member 2B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of INSYN2B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:18,916,721...19,023,859
Ensembl chr10:19,003,131...19,022,139
|
|
G |
Iqch |
IQ motif containing H |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of IQCH mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:63,889,816...64,083,248
Ensembl chr 8:63,892,370...64,083,223
|
|
G |
Irag1 |
inositol 1,4,5-triphosphate receptor associated 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of IRAG1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:164,981,716...165,094,232
Ensembl chr 1:164,981,716...165,094,176
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of ISL1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
|
|
G |
Ism2 |
isthmin 2 |
increases expression |
ISO |
Pioglitazone results in increased expression of ISM2 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 6:106,921,213...106,944,291
Ensembl chr 6:106,926,175...106,944,514
|
|
G |
Itga8 |
integrin subunit alpha 8 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ITGA8 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510
|
|
G |
Itgav |
integrin subunit alpha V |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ITGAV mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Itgb1bp2 |
integrin subunit beta 1 binding protein 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ITGB1BP2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:66,572,537...66,577,174
Ensembl chr X:66,572,537...66,577,174
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ITIH2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841
|
|
G |
Itln1 |
intelectin 1 |
increases expression |
ISO |
pioglitazone results in increased expression of ITLN1 protein |
CTD |
PMID:23555749 |
|
NCBI chr13:83,932,234...83,958,243
Ensembl chr13:83,948,124...83,958,227
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of JCHAIN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:19,538,927...19,547,023
Ensembl chr14:19,538,952...19,546,298
|
|
G |
Jph2 |
junctophilin 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of JPH2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:151,994,768...152,058,941
Ensembl chr 3:151,994,778...152,058,904
|
|
G |
Jsrp1 |
junctional sarcoplasmic reticulum protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of JSRP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:8,889,486...8,906,055
Ensembl chr 7:8,901,609...8,906,055
|
|
G |
Kank4 |
KN motif and ankyrin repeat domains 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KANK4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KCNB1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KCNC4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233
|
|
G |
Kcnd3 |
potassium voltage-gated channel subfamily D member 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KCND3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:192,937,950...193,155,345
Ensembl chr 2:192,937,950...193,155,345
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KCNJ11 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Kcnj13 |
potassium inwardly-rectifying channel, subfamily J, member 13 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KCNJ13 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:88,063,003...88,071,112
Ensembl chr 9:88,063,003...88,071,112
|
|
G |
Klf2 |
KLF transcription factor 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of KLF2 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of KLF2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klf5 |
KLF transcription factor 5 |
multiple interactions |
EXP |
Pioglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 mRNA]; Pioglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 protein] |
CTD |
PMID:25874449 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klhl13 |
kelch-like family member 13 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KLHL13 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:113,942,309...114,107,299
Ensembl chr X:113,942,309...114,107,321
|
|
G |
Klhl31 |
kelch-like family member 31 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KLHL31 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:78,515,514...78,538,873
Ensembl chr 8:78,515,514...78,538,873
|
|
G |
Klhl40 |
kelch-like family member 40 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KLHL40 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:121,441,285...121,446,801
Ensembl chr 8:121,441,287...121,446,800
|
|
G |
Klhl41 |
kelch-like family member 41 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KLHL41 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:54,434,291...54,447,415
Ensembl chr 3:54,434,234...54,449,222
|
|
G |
Klk6 |
kallikrein related-peptidase 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of KLK6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:94,278,863...94,286,136
Ensembl chr 1:94,280,340...94,286,121
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of KRT16 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt20 |
keratin 20 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of KRT20 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:84,384,790...84,394,125
Ensembl chr10:84,384,802...84,394,107
|
|
G |
Krt84 |
keratin 84 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of KRT84 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:132,649,064...132,656,885
Ensembl chr 7:132,649,061...132,656,874
|
|
G |
Krt90 |
keratin 90 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in increased expression of KRT90 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:132,677,994...132,686,634
Ensembl chr 7:132,677,751...132,686,759
|
|
G |
Ky |
kyphoscoliosis peptidase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of KY mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:103,086,959...103,126,305
Ensembl chr 8:103,086,630...103,126,024
|
|
G |
Lama2 |
laminin subunit alpha 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LAMA2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530
|
|
G |
Larp6 |
La ribonucleoprotein 6, translational regulator |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LARP6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:61,183,744...61,205,548
Ensembl chr 8:61,184,116...61,205,535
|
|
G |
Lce1f |
late cornified envelope 1F |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of LCE1F mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:178,305,786...178,307,372
Ensembl chr 2:178,305,786...178,307,372
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression multiple interactions |
ISO |
pioglitazone results in increased expression of LDLR protein [pioglitazone co-treated with U 0126] affects the localization of LDLR protein |
CTD |
PMID:22593575 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
increases expression |
EXP |
pioglitazone results in increased expression of LEP protein |
CTD |
PMID:15655531 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
increases response to substance multiple interactions |
EXP ISO |
LEPR gene mutant form results in increased susceptibility to Pioglitazone Pioglitazone inhibits the reaction [LEPR protein affects the expression of OGG1 protein]; Pioglitazone inhibits the reaction [LEPR protein affects the expression of XRCC1 protein] |
CTD |
PMID:29743445 PMID:35472412 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lgi1 |
leucine-rich, glioma inactivated 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LGI1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:236,043,269...236,084,617
Ensembl chr 1:236,042,954...236,084,616
|
|
G |
Lhfpl4 |
LHFPL tetraspan subfamily member 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LHFPL4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:146,317,110...146,340,073
Ensembl chr 4:146,313,541...146,340,463
|
|
G |
Lipc |
lipase C, hepatic type |
increases expression |
ISO |
pioglitazone results in increased expression of LIPC mRNA |
CTD |
PMID:20503262 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipf |
lipase F, gastric type |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LIPF mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:231,493,498...231,511,845
Ensembl chr 1:231,493,498...231,511,845
|
|
G |
Lipn |
lipase, family member N |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of LIPN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:231,584,950...231,603,456
Ensembl chr 1:231,584,956...231,603,468
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of LITAF mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of LITAF mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Lman1l |
lectin, mannose-binding, 1 like |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LMAN1L mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:58,010,839...58,029,599
Ensembl chr 8:58,010,839...58,023,681
|
|
G |
Lmod3 |
leiomodin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LMOD3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:129,843,964...129,858,684
Ensembl chr 4:129,843,970...129,858,244
|
|
G |
LOC120098377 |
U1 spliceosomal RNA |
decreases expression |
ISO |
Pioglitazone results in decreased expression of RNVU1-7 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr18:79,901,335...79,901,477
Ensembl chr18:79,901,335...79,901,477 Ensembl chr18:79,901,335...79,901,477
|
|
G |
Lrrc39 |
leucine rich repeat containing 39 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LRRC39 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:204,516,122...204,535,463
Ensembl chr 2:204,516,123...204,535,463
|
|
G |
Lrrc3b |
leucine rich repeat containing 3B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LRRC3B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:9,973,580...10,050,891
Ensembl chr15:9,969,983...10,051,066
|
|
G |
Lrrn1 |
leucine rich repeat neuronal 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LRRN1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:140,476,752...140,520,210
Ensembl chr 4:140,476,324...140,518,620
|
|
G |
Lrrn3 |
leucine rich repeat neuronal 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of LRRN3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330
|
|
G |
Magix |
MAGI family member, X-linked |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MAGIX mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:14,824,114...14,832,466
Ensembl chr X:14,824,188...14,831,045
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions |
ISO |
pioglitazone binds to and results in decreased activity of MAOB protein |
CTD |
PMID:22282722 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
EXP ISO |
pioglitazone inhibits the reaction [Streptozocin results in increased expression of MAPK1 mRNA]; pioglitazone inhibits the reaction [Streptozocin results in increased expression of MAPK1 protein]; pioglitazone results in increased phosphorylation of and results in increased activity of MAPK1 protein [PDGFB protein binds to PDGFB protein] inhibits the reaction [pioglitazone results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:11687581 PMID:17063547 PMID:26643070 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
EXP ISO |
pioglitazone results in increased phosphorylation of and results in increased activity of MAPK3 protein pioglitazone results in decreased phosphorylation of MAPK3 protein [PDGFB protein binds to PDGFB protein] inhibits the reaction [pioglitazone results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:11687581 PMID:26643070 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mb |
myoglobin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MB mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mb21d2 |
Mab-21 domain containing 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of MB21D2 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr11:71,825,748...71,924,770
Ensembl chr11:71,825,748...71,924,769
|
|
G |
Mcemp1 |
mast cell-expressed membrane protein 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of MCEMP1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr12:1,721,781...1,727,350
Ensembl chr12:1,718,730...1,725,986
|
|
G |
Mcidas |
multiciliate differentiation and DNA synthesis associated cell cycle protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MCIDAS mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:44,636,820...44,644,551
Ensembl chr 2:44,636,856...44,642,601
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MEF2C mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
Pioglitazone results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mettl21cl1 |
methyltransferase like 21C-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of METTL21E mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:46,382,141...46,397,299
Ensembl chr 9:46,383,687...46,397,266
|
|
G |
Mfap4 |
microfibril associated protein 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MFAP4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155
|
|
G |
Mgam |
maltase-glucoamylase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in increased expression of MGAM mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:69,441,626...69,602,068
Ensembl chr 4:69,446,150...69,692,715
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
ISO |
[Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR133B mRNA |
CTD |
PMID:28263783 |
|
NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
ISO |
[Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR206 mRNA |
CTD |
PMID:28263783 |
|
NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332
|
|
G |
Mlip |
muscular LMNA-interacting protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MLIP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:77,935,087...78,204,725
Ensembl chr 8:77,935,079...78,204,254
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MME mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of MMP12 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
EXP |
pioglitazone affects the reaction [Carbon Tetrachloride results in increased cleavage of MMP13 protein] |
CTD |
PMID:16484506 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
multiple interactions decreases expression |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of MMP7 mRNA Pioglitazone results in decreased expression of MMP7 mRNA |
CTD |
PMID:27935865 PMID:30031879 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of MMP8 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases secretion decreases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]]; pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein] pioglitazone results in decreased secretion of MMP9 protein Pioglitazone results in decreased expression of MMP9 mRNA |
CTD |
PMID:16860414 PMID:17055343 PMID:30031879 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Ms4a7 |
membrane spanning 4-domains A7 |
increases expression |
ISO |
Pioglitazone results in increased expression of MS4A7 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 1:207,969,117...207,984,743
Ensembl chr 1:207,968,761...207,983,260
|
|
G |
Mstn |
myostatin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MSTN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Mtarc1 |
mitochondrial amidoxime reducing component 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of MTARC1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of MTOR mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc1 |
mucin 1, cell surface associated |
decreases expression |
ISO |
Pioglitazone results in decreased expression of MUC1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Muc5b |
mucin 5B, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MUC5B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:196,916,861...196,948,830
Ensembl chr 1:196,916,825...196,949,250
|
|
G |
Mucl3 |
mucin like 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of MUCL3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:3,100,652...3,108,569
Ensembl chr20:3,100,679...3,108,569
|
|
G |
Mxd1 |
max dimerization protein 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of MXD1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of MXD1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 4:119,097,353...119,118,080
Ensembl chr 4:119,097,353...119,117,751
|
|
G |
Mybpc1 |
myosin binding protein C1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYBPC1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:22,930,350...23,015,981
Ensembl chr 7:22,930,350...23,015,957
|
|
G |
Myf6 |
myogenic factor 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYF6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:42,813,008...42,814,852
Ensembl chr 7:42,812,792...42,814,852
|
|
G |
Myh1 |
myosin heavy chain 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYH1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:51,885,913...51,909,699
Ensembl chr10:51,885,913...51,946,295
|
|
G |
Myh11 |
myosin heavy chain 11 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYH11 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:743,364...838,459
Ensembl chr10:743,685...838,459
|
|
G |
Myh13 |
myosin heavy chain 13 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYH13 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:52,012,779...52,068,960
Ensembl chr10:52,009,425...52,068,951
|
|
G |
Myh2 |
myosin heavy chain 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYH2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:51,856,738...51,883,236
Ensembl chr10:51,856,738...51,883,236
|
|
G |
Myh4 |
myosin heavy chain 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of MYH4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:51,923,149...51,946,297
Ensembl chr10:51,885,913...51,946,295
|
|
G |
Myl1 |
myosin, light chain 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:68,437,514...68,458,256
Ensembl chr 9:68,437,517...68,458,261
|
|
G |
Myl11 |
myosin light chain 11 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of MYLPF mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:181,829,703...181,832,546
Ensembl chr 1:181,829,743...181,832,545
|
|
G |
Myl9 |
myosin light chain 9 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYL9 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYLK mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Myo18b |
myosin XVIIIb |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYO18B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:43,747,003...43,953,694
Ensembl chr12:43,747,010...43,953,695
|
|
G |
Myo1c |
myosin 1C |
increases expression |
ISO |
Pioglitazone results in increased expression of MYO1C mRNA |
CTD |
PMID:32589349 |
|
NCBI chr10:60,498,372...60,520,752
Ensembl chr10:60,498,280...60,520,752
|
|
G |
Myom1 |
myomesin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYOM1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:110,916,156...111,039,344
Ensembl chr 9:110,915,943...111,039,344
|
|
G |
Myom2 |
myomesin 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYOM2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:74,520,148...74,592,658
Ensembl chr16:74,520,157...74,592,772
|
|
G |
Myom3 |
myomesin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYOM3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:147,992,737...148,043,282
Ensembl chr 5:147,992,737...148,043,274
|
|
G |
Myot |
myotilin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYOT mRNA |
CTD |
PMID:27935865 |
|
NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841
|
|
G |
Myoz1 |
myozenin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYOZ1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:3,644,333...3,651,584
Ensembl chr15:3,644,368...3,652,884
|
|
G |
Myoz3 |
myozenin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYOZ3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr18:54,026,133...54,046,151
Ensembl chr18:54,026,152...54,102,126
|
|
G |
Mypn |
myopalladin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYPN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:25,429,898...25,522,443
Ensembl chr20:25,436,843...25,522,443
|
|
G |
Mzb1 |
marginal zone B and B1 cell-specific protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MZB1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr18:27,238,999...27,241,060
Ensembl chr18:27,239,001...27,241,094
|
|
G |
Naalad2 |
N-acetylated alpha-linked acidic dipeptidase 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NAALAD2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:15,406,119...15,479,714
Ensembl chr 8:15,407,043...15,479,714
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of NDRG1 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Neb |
nebulin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NEB mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:36,613,716...36,811,574
|
|
G |
Negr1 |
neuronal growth regulator 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NEGR1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:245,624,460...246,359,605
Ensembl chr 2:245,624,435...246,356,730
|
|
G |
Nexn |
nexilin (F actin binding protein) |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NEXN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:241,186,783...241,218,315
Ensembl chr 2:241,186,790...241,218,342
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 protein promotes the reaction [Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of NQO1 mRNA]]; NFE2L2 protein promotes the reaction [Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of NQO1 protein]]; Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NFE2L2 mRNA]; Pioglitazone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30965670 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIB protein] |
CTD |
PMID:17055343 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nkain3 |
Sodium/potassium transporting ATPase interacting 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NKAIN3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:33,613,720...34,310,090
Ensembl chr 5:33,623,713...34,309,381
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NKX3-1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nmrk2 |
nicotinamide riboside kinase 2 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of NMRK2 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 7:8,514,855...8,517,916
Ensembl chr 7:8,514,927...8,517,922
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression affects expression |
ISO EXP |
pioglitazone inhibits the reaction [Homocysteine results in increased methylation of NOS2 promoter] Pioglitazone inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of NOS2 protein]; Pioglitazone inhibits the reaction [Endotoxins results in increased expression of NOS2 protein] pioglitazone results in decreased expression of NOS2 mRNA pioglitazone affects the expression of NOS2 |
CTD |
PMID:15364003 PMID:15817521 PMID:17492134 PMID:21962020 PMID:30343038 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
Pioglitazone inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of NOS3 protein] |
CTD |
PMID:30343038 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
affects activity |
ISO |
pioglitazone affects the activity of NOX1 protein |
CTD |
PMID:21962020 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [Streptozocin results in increased expression of NOX4 mRNA] |
CTD |
PMID:16979161 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
increases expression |
EXP |
Pioglitazone results in increased expression of NPHS1 mRNA; Pioglitazone results in increased expression of NPHS1 protein |
CTD |
PMID:16687628 |
|
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
ISO |
Pioglitazone results in decreased expression of NPPB mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Npy |
neuropeptide Y |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of NPY mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Npy1r |
neuropeptide Y receptor Y1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NPY1R mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
NFE2L2 protein promotes the reaction [Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of NQO1 mRNA]]; NFE2L2 protein promotes the reaction [Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of NQO1 protein]]; Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of NQO1 mRNA]; Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of NQO1 protein]; Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NQO1 mRNA] |
CTD |
PMID:30965670 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
increases expression |
ISO |
pioglitazone results in increased expression of NR1H2 mRNA |
CTD |
PMID:19201410 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions affects response to substance increases expression |
ISO |
22-hydroxycholesterol promotes the reaction [pioglitazone results in increased expression of NR1H3 mRNA]; NR1H3 protein affects the reaction [pioglitazone results in increased expression of PPARA mRNA] NR1H3 protein affects the susceptibility to pioglitazone |
CTD |
PMID:15381068 PMID:19201410 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects localization |
ISO |
Pioglitazone affects the localization of NR1I2 protein |
CTD |
PMID:31233785 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
ISO |
pioglitazone results in increased expression of NR4A1 mRNA |
CTD |
PMID:17785466 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
increases expression |
ISO |
pioglitazone results in increased expression of NR4A3 mRNA |
CTD |
PMID:17785466 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nrap |
nebulin-related anchoring protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NRAP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:255,350,113...255,427,693
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of NSG2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:15,601,594...15,661,441
Ensembl chr10:15,601,596...15,661,441
|
|
G |
Nucb2 |
nucleobindin 2 |
increases stability |
ISO |
pioglitazone results in increased stability of NUCB2 mRNA |
CTD |
PMID:20427483 |
|
NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
|
|
G |
Obscn |
obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of OBSCN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions |
ISO |
Pioglitazone inhibits the reaction [LEPR protein affects the expression of OGG1 protein] |
CTD |
PMID:35472412 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Olfml1 |
olfactomedin-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of OLFML1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:161,478,129...161,502,541
Ensembl chr 1:161,478,242...161,502,537
|
|
G |
Opcml |
opioid binding protein/cell adhesion molecule-like |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of OPCML mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:26,788,988...27,304,551
Ensembl chr 8:26,192,841...27,300,620
|
|
G |
Optc |
opticin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of OPTC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:45,353,954...45,368,254
Ensembl chr13:45,355,148...45,365,237
|
|
G |
Pax1 |
paired box 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PAX1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:134,792,330...134,801,637
Ensembl chr 3:134,789,182...134,801,636
|
|
G |
Pcdh18 |
protocadherin 18 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PCDH18 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PCK1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pclo |
piccolo (presynaptic cytomatrix protein) |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PCLO mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:19,691,439...20,050,015
Ensembl chr 4:19,695,315...20,049,885
|
|
G |
PCOLCE2 |
procollagen C-endopeptidase enhancer 2 |
increases expression |
ISO |
Pioglitazone results in increased expression of PCOLCE2 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 8:96,193,461...96,251,116
Ensembl chr 8:96,193,461...96,251,114
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions increases expression |
ISO |
pioglitazone promotes the reaction [PPARG protein results in increased expression of PCSK9 mRNA] pioglitazone results in increased expression of PCSK9 mRNA; pioglitazone results in increased expression of PCSK9 protein [pioglitazone co-treated with U 0126] results in increased secretion of PCSK9 protein |
CTD |
PMID:22593575 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pde6c |
phosphodiesterase 6C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PDE6C mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:235,909,583...235,965,435
Ensembl chr 1:235,909,775...235,965,315
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[PDGFB protein binds to PDGFB protein] inhibits the reaction [pioglitazone results in decreased phosphorylation of MAPK1 protein]; [PDGFB protein binds to PDGFB protein] inhibits the reaction [pioglitazone results in decreased phosphorylation of MAPK3 protein]; pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased degradation of CDKN1B protein]; pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of CCND1 protein]; pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of CDKN1A protein]; pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of EIF4EBP1 protein]; pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RPS6 protein]; pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RPS6KB1 protein]; PRKAA1 protein affects the reaction [pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RPS6 protein]] |
CTD |
PMID:26643070 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PDGFRA mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Pioglitazone results in increased expression of PDK4 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Peg10 |
paternally expressed 10 |
increases expression |
ISO |
Pioglitazone results in increased expression of PEG10 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Perm1 |
PPARGC1 and ESRR induced regulator, muscle 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PERM1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:166,800,030...166,805,323
Ensembl chr 5:166,800,030...166,805,323
|
|
G |
Pgam2 |
phosphoglycerate mutase 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PGAM2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:80,681,796...80,683,907
Ensembl chr14:80,681,776...80,683,940
|
|
G |
Pgm5 |
phosphoglucomutase 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PGM5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:222,325,638...222,513,434
Ensembl chr 1:222,325,643...222,513,437
|
|
G |
Phactr1 |
phosphatase and actin regulator 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PHACTR1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:21,560,364...22,040,166
Ensembl chr17:21,562,721...22,039,831
|
|
G |
Pheta2 |
PH domain containing endocytic trafficking adaptor 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PHETA2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:113,855,437...113,861,910
Ensembl chr 7:113,857,249...113,861,871
|
|
G |
Phex |
phosphate regulating endopeptidase X-linked |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PHEX mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Phgr1 |
proline, histidine and glycine rich 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of PHGR1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:105,742,822...105,760,835
Ensembl chr 3:105,757,581...105,760,832
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Piezo2 |
piezo-type mechanosensitive ion channel component 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PIEZO2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr18:56,468,449...56,844,984
Ensembl chr18:56,469,680...56,844,216
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of PIK3C3 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions decreases expression |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of PIK3CA mRNA Pioglitazone results in decreased expression of PIK3CA mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of PIK3CB mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of PIK3CG mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pknox2 |
PBX/knotted 1 homeobox 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PKNOX2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:36,600,633...36,863,131
Ensembl chr 8:36,600,636...36,790,940
|
|
G |
Plaat1 |
phospholipase A and acyltransferase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of PLAAT1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:71,517,492...71,537,142
Ensembl chr11:71,517,493...71,527,020
|
|
G |
Pld1 |
phospholipase D1 |
decreases expression multiple interactions |
ISO |
Pioglitazone results in decreased expression of PLD1 mRNA [Metformin co-treated with Pioglitazone] results in decreased expression of PLD1 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Plek |
pleckstrin |
decreases expression |
ISO |
Pioglitazone results in decreased expression of PLEK mRNA |
CTD |
PMID:30031879 |
|
NCBI chr14:91,397,015...91,429,693
Ensembl chr14:91,397,019...91,454,131
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of PLIN1 mRNA; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA] |
CTD |
PMID:27935865 PMID:32473317 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO |
Pioglitazone results in increased expression of PLIN2 mRNA |
CTD |
PMID:15381068 PMID:30031879 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Plin4 |
perilipin 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PLIN4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:929,168...938,062
Ensembl chr 9:929,176...938,056
|
|
G |
Pln |
phospholamban |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PLN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:32,629,537...32,639,559
|
|
G |
Pnma8b |
PNMA family member 8B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of PNMA8B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:77,622,287...77,626,525
Ensembl chr 1:77,622,283...77,627,148
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
EXP |
pioglitazone results in increased expression of POR mRNA |
CTD |
PMID:16597547 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases expression affects response to substance affects binding increases activity |
EXP ISO |
pioglitazone binds to and results in increased activity of PPARA protein NR1H3 protein affects the reaction [pioglitazone results in increased expression of PPARA mRNA]; pioglitazone results in increased activity of [PPARA protein binds to RXRA protein] pioglitazone results in increased expression of PPARA mRNA; pioglitazone results in increased expression of PPARA protein PPARA protein affects the susceptibility to pioglitazone pioglitazone binds to PPARA protein pioglitazone results in increased activity of PPARA protein |
CTD |
PMID:11172467 PMID:11779144 PMID:15273253 PMID:16751799 PMID:19201410 PMID:23150725 PMID:23843199 More...
|
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding increases expression multiple interactions increases activity |
ISO |
pioglitazone binds to PPARB protein; pioglitazone binds to PPARD protein pioglitazone results in increased expression of PPARD mRNA pioglitazone results in increased activity of [PPARD protein binds to RXRA protein] pioglitazone results in increased activity of PPARD protein |
CTD |
PMID:11779144 PMID:19201410 PMID:23150725 PMID:23843199 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions affects expression affects response to substance increases activity increases expression affects binding |
ISO EXP |
[Dexamethasone co-treated with INS protein co-treated with Pioglitazone] results in increased expression of PPARG protein; Ethanol inhibits the reaction [Pioglitazone results in increased activity of PPARG protein]; GW 1929 inhibits the reaction [Pioglitazone results in increased expression of PPARG protein]; luzindole inhibits the reaction [Pioglitazone results in increased expression of PPARG protein]; Melatonin promotes the reaction [Pioglitazone results in increased expression of PPARG protein]; Pioglitazone binds to and results in increased activity of PPARG protein; Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of PPARG protein]; Pioglitazone inhibits the reaction [GW 1929 binds to PPARG protein]; Pioglitazone promotes the reaction [Melatonin results in increased expression of PPARG protein]; Pioglitazone promotes the reaction [PPARG protein binds to NPHS1 promoter]; Pioglitazone promotes the reaction [PPARG protein results in increased expression of PCSK9 mRNA]; Pioglitazone results in increased activity of [PPARG protein alternative form binds to RXRA protein]; PPARG protein affects the reaction [Pioglitazone results in increased expression of CD36 protein]; PPARG protein promotes the reaction [Pioglitazone results in increased activity of DIO2 protein]; Ro 41-5253 inhibits the reaction [Pioglitazone results in increased activity of PPARG protein] [ANGPT2 protein binds to and results in increased activity of AGTR2 protein] promotes the reaction [pioglitazone binds to and results in increased activity of PPARG protein]; [Dexamethasone co-treated with INS protein co-treated with pioglitazone] results in increased expression of PPARG protein; [pioglitazone binds to and results in increased activity of PPARG protein] which results in increased expression of RETSAT mRNA; [pioglitazone co-treated with alitretinoin] inhibits the reaction [PPARG protein results in increased susceptibility to Methamphetamine]; pioglitazone binds to and results in increased activity of PPARG protein; pioglitazone inhibits the reaction [PPARG protein results in increased susceptibility to Methamphetamine]; pioglitazone promotes the reaction [PPARG protein binds to SCNN1G intron]; pioglitazone promotes the reaction [Toluene 2,4-Diisocyanate results in increased localization of PPARG protein]; pioglitazone results in increased activity of and results in decreased expression of PPARG protein; PPARG protein affects the reaction [pioglitazone results in increased expression of ADIPOQ mRNA] pioglitazone affects the expression of PPARG; pioglitazone affects the expression of PPARG mRNA 2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone affects the expression of PPARG mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone affects the expression of PPARG protein]; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of PPARG mRNA]; [Pioglitazone binds to and results in increased activity of PPARG protein] promotes the reaction [Dietary Fats results in increased abundance of Diglycerides]; [Pioglitazone binds to and results in increased activity of PPARG protein] promotes the reaction [Dietary Fats results in increased abundance of Phospholipids]; [Pioglitazone binds to and results in increased activity of PPARG protein] promotes the reaction [Dietary Fats results in increased abundance of Triglycerides]; [Pioglitazone results in increased activity of PPARG protein] which results in decreased abundance of Triglycerides; [Pioglitazone results in increased activity of PPARG protein] which results in increased abundance of Diglycerides; Pioglitazone affects the reaction [Puromycin Aminonucleoside results in increased expression of PPARG protein]; Pioglitazone binds to and results in increased activity of PPARG protein; Pioglitazone inhibits the reaction [[Ethanol co-treated with Lipopolysaccharides] results in decreased expression of PPARG mRNA]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of PPARG mRNA]; Pioglitazone inhibits the reaction [Carbon Tetrachloride results in decreased expression of PPARG mRNA]; Pioglitazone inhibits the reaction [Cisplatin results in decreased expression of PPARG mRNA]; Pioglitazone inhibits the reaction [Fructose results in decreased activity of PPARG protein]; Pioglitazone inhibits the reaction [Quinolinic Acid results in decreased expression of PPARG mRNA]; Pioglitazone inhibits the reaction [Streptozocin results in decreased expression of PPARG protein]; T 0070907 inhibits the reaction [Pioglitazone affects the expression of PPARG mRNA]; T 0070907 inhibits the reaction [Pioglitazone affects the expression of PPARG protein] PPARG protein affects the susceptibility to pioglitazone pioglitazone results in increased activity of PPARG protein Pioglitazone results in increased expression of PPARG mRNA; Pioglitazone results in increased expression of PPARG mRNA alternative form; Pioglitazone results in increased expression of PPARG protein pioglitazone results in increased expression of PPARG mRNA Pioglitazone binds to PPARG protein pioglitazone affects the expression of PPARG mRNA; pioglitazone affects the expression of PPARG protein |
CTD |
PMID:9836514 PMID:11172467 PMID:11779144 PMID:11991651 PMID:12055599 PMID:12927809 PMID:15150131 PMID:15273253 PMID:15318101 PMID:15729575 PMID:15992368 PMID:16007095 PMID:16324916 PMID:16407166 PMID:16598202 PMID:16687628 PMID:16751799 PMID:17015710 PMID:17019405 PMID:17030193 PMID:17084873 PMID:17290005 PMID:19036883 PMID:19048458 PMID:19139408 PMID:19201410 PMID:19403437 PMID:19439812 PMID:20064974 PMID:20307981 PMID:20860658 PMID:21354099 PMID:21557540 PMID:21597168 PMID:21962020 PMID:22070604 PMID:22593575 PMID:22989705 PMID:23150725 PMID:23795773 PMID:23811337 PMID:23843199 PMID:25679220 PMID:26643070 PMID:27350165 PMID:28744220 PMID:29669060 PMID:29734669 PMID:30130594 PMID:30965670 PMID:31016361 PMID:32407875 PMID:32473317 PMID:37044004 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression multiple interactions |
EXP ISO |
pioglitazone results in decreased expression of PPARGC1A mRNA Pioglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of PPARGC1A protein] |
CTD |
PMID:22456468 PMID:27366949 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppbp |
pro-platelet basic protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of PPBP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:17,302,326...17,303,130
Ensembl chr14:17,302,326...17,303,130
|
|
G |
Ppp1r3a |
protein phosphatase 1, regulatory subunit 3A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PPP1R3A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:42,937,353...42,980,195
Ensembl chr 4:42,939,599...42,980,638
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
increases expression |
ISO |
Pioglitazone results in increased expression of PPP2CA mRNA |
CTD |
PMID:32589349 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
increases expression |
ISO |
Pioglitazone results in increased expression of PPP2R2B mRNA |
CTD |
PMID:32589349 |
|
NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
PRKAA1 protein affects the reaction [pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RPS6 protein]]; PRKAA1 protein affects the reaction [pioglitazone results in increased expression of CDKN1B protein]; PRKAA1 protein affects the reaction [pioglitazone results in increased phosphorylation of RPTOR protein] |
CTD |
PMID:26643070 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions decreases expression |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of PRKCA mRNA Pioglitazone results in decreased expression of PRKCA mRNA |
CTD |
PMID:32589349 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcg |
protein kinase C, gamma |
increases expression |
ISO |
Pioglitazone results in increased expression of PRKCG mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Prkcq |
protein kinase C, theta |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PRKCQ mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:67,246,394...67,379,049
Ensembl chr17:67,246,394...67,378,704
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PRKG1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Prnp |
prion protein |
increases expression multiple interactions |
ISO |
Pioglitazone results in increased expression of PRNP protein GW 1929 inhibits the reaction [Pioglitazone results in increased expression of PRNP protein]; luzindole inhibits the reaction [Pioglitazone results in increased expression of PRNP protein]; Melatonin promotes the reaction [Pioglitazone results in increased expression of PRNP protein]; Pioglitazone promotes the reaction [Melatonin results in increased expression of PRNP protein]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]] |
CTD |
PMID:29734669 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
G |
Prok2 |
prokineticin 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of PROK2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:132,346,681...132,361,754
Ensembl chr 4:132,347,103...132,361,385
|
|
G |
Prr32 |
proline rich 32 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PRR32 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:123,978,010...123,979,928
Ensembl chr X:123,977,985...123,979,942
|
|
G |
Prr33 |
proline rich 33 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PRR33 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:197,644,903...197,650,774
Ensembl chr 1:197,644,902...197,650,714
|
|
G |
Prxl2b |
peroxiredoxin like 2B |
decreases expression |
ISO |
Pioglitazone results in decreased expression of PRXL2B mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 5:165,462,610...165,465,213
|
|
G |
Psors1c2 |
psoriasis susceptibility 1 candidate 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of PSORS1C2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:3,202,178...3,203,599
Ensembl chr20:3,202,174...3,203,599
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
Pioglitazone results in increased expression of PTEN mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgfr |
prostaglandin F receptor |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PTGFR mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:240,733,375...240,765,650
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression increases expression |
EXP ISO |
[Atorvastatin co-treated with Pioglitazone] results in increased expression of PTGS2 protein pioglitazone results in decreased expression of PTGS2 mRNA pioglitazone results in decreased expression of PTGS2 protein Pioglitazone results in increased expression of PTGS2 mRNA |
CTD |
PMID:15817521 PMID:16386242 PMID:16908763 PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pvalb |
parvalbumin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PVALB mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Pxmp2 |
peroxisomal membrane protein 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PXMP2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:46,394,051...46,404,561
Ensembl chr12:46,394,193...46,404,557
|
|
G |
Pygm |
glycogen phosphorylase, muscle associated |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PYGM mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:203,690,550...203,705,369
Ensembl chr 1:203,690,533...203,705,368
|
|
G |
Ralyl |
RALY RNA binding protein-like |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RALYL mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:87,482,747...88,274,329
Ensembl chr 2:87,482,755...88,274,452
|
|
G |
Ranbp2 |
RAN binding protein 2 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of RANBP2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr20:26,442,156...26,493,481
Ensembl chr20:26,442,217...26,493,481
|
|
G |
Rasd2 |
RASD family, member 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RASD2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr19:13,594,291...13,605,016
Ensembl chr19:13,594,291...13,605,016
|
|
G |
Rasl12 |
RAS-like, family 12 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RASL12 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:65,917,840...65,931,885
Ensembl chr 8:65,917,840...65,932,741
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
pioglitazone results in decreased phosphorylation of and results in decreased expression of RB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rcan2 |
regulator of calcineurin 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RCAN2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:16,959,478...17,174,823
Ensembl chr 9:16,959,480...17,174,856
|
|
G |
Rdh10 |
retinol dehydrogenase 10 |
increases expression |
ISO |
Pioglitazone results in increased expression of RDH10 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 5:3,186,671...3,215,572
Ensembl chr 5:3,188,445...3,215,572
|
|
G |
Reep3 |
receptor accessory protein 3 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of REEP3 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr20:21,493,868...21,578,698
Ensembl chr20:21,493,954...21,578,697
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects expression |
ISO EXP |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased localization of RELA protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone affects the expression of RELA mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone affects the expression of RELA protein]; Fenofibrate promotes the reaction [Pioglitazone inhibits the reaction [Doxorubicin results in increased expression of RELA protein]]; Pioglitazone inhibits the reaction [Aldosterone results in increased activity of RELA protein]; Pioglitazone inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Pioglitazone inhibits the reaction [Streptozocin results in increased expression of RELA mRNA]; Pioglitazone promotes the reaction [Fenofibrate inhibits the reaction [Doxorubicin results in increased expression of RELA protein]]; T 0070907 inhibits the reaction [Pioglitazone affects the expression of RELA mRNA]; T 0070907 inhibits the reaction [Pioglitazone affects the expression of RELA protein] Pioglitazone affects the expression of RELA mRNA; Pioglitazone affects the expression of RELA protein |
CTD |
PMID:17015710 PMID:18660453 PMID:28744220 PMID:36988379 PMID:37044004 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retn |
resistin |
multiple interactions increases expression increases secretion |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of RETN mRNA; Pioglitazone inhibits the reaction [Sodium Glutamate results in increased expression of RETN mRNA]; Pioglitazone inhibits the reaction [Sodium Glutamate results in increased secretion of RETN protein] Pioglitazone results in increased expression of RETN mRNA Pioglitazone results in increased secretion of RETN protein |
CTD |
PMID:27918843 PMID:27935865 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Retsat |
retinol saturase |
multiple interactions increases expression |
ISO |
[pioglitazone binds to and results in increased activity of PPARG protein] which results in increased expression of RETSAT mRNA Pioglitazone results in increased expression of RETSAT mRNA; Pioglitazone results in increased expression of RETSAT protein |
CTD |
PMID:19139408 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
Rgcc |
regulator of cell cycle |
decreases expression |
ISO |
Pioglitazone results in decreased expression of RGCC mRNA |
CTD |
PMID:30031879 |
|
NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141
|
|
G |
Rgn |
regucalcin |
multiple interactions |
ISO |
Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]; Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]; Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]] |
CTD |
PMID:29734669 |
|
NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450
|
|
G |
Rgs1 |
regulator of G-protein signaling 1 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of RGS1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr13:56,018,546...56,022,889
Ensembl chr13:56,018,554...56,022,984
|
|
G |
Rgs13 |
regulator of G-protein signaling 13 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RGS13 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:55,922,290...55,955,753
Ensembl chr13:55,922,395...55,955,648
|
|
G |
Rgs5 |
regulator of G-protein signaling 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RGS5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518
|
|
G |
Rgs7bp |
regulator of G-protein signaling 7 binding protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RGS7BP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505
|
|
G |
Rheb |
Ras homolog, mTORC1 binding |
increases expression |
ISO |
Pioglitazone results in increased expression of RHEB mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 4:10,278,970...10,320,160
Ensembl chr 4:10,279,370...10,320,160
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of RICTOR mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of RICTOR mRNA] |
CTD |
PMID:20847119 PMID:32589349 |
|
NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426
|
|
G |
Riox1 |
ribosomal oxygenase 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of RIOX1 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 6:103,579,642...103,582,260
Ensembl chr 6:103,579,642...103,582,250
|
|
G |
Rnase6 |
ribonuclease A family member 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RNASE6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:24,354,305...24,357,289
Ensembl chr15:24,354,303...24,357,328
|
|
G |
Robo3 |
roundabout guidance receptor 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of ROBO3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:37,133,542...37,151,674
Ensembl chr 8:37,133,916...37,151,315
|
|
G |
Rorc |
RAR-related orphan receptor C |
increases expression |
ISO |
pioglitazone results in increased expression of RORC mRNA |
CTD |
PMID:9543393 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Rpl3l |
ribosomal protein L3-like |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RPL3L mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:13,753,914...13,764,458
Ensembl chr10:13,753,886...13,764,457
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation multiple interactions decreases expression |
ISO |
pioglitazone results in decreased phosphorylation of RPS6 protein pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RPS6 protein]; PRKAA1 protein affects the reaction [pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RPS6 protein]] Pioglitazone results in decreased expression of RPS6 mRNA |
CTD |
PMID:26643070 PMID:32589349 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
increases expression |
ISO |
Pioglitazone results in increased expression of RPS6KA1 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression multiple interactions |
ISO |
Pioglitazone results in increased expression of RPS6KA2 mRNA [Metformin co-treated with Pioglitazone] results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
Rps6ka5 |
ribosomal protein S6 kinase A5 |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of RPS6KA5 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
ISO |
pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of RPS6KB1 protein] pioglitazone results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:26643070 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
increases phosphorylation multiple interactions |
ISO |
pioglitazone results in increased phosphorylation of RPTOR protein PRKAA1 protein affects the reaction [pioglitazone results in increased phosphorylation of RPTOR protein] |
CTD |
PMID:26643070 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Rpusd2 |
RNA pseudouridine synthase domain containing 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of RPUSD2 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 3:106,017,759...106,023,010
Ensembl chr 3:106,017,864...106,023,251
|
|
G |
Rspo1 |
R-spondin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RSPO1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:137,251,629...137,273,273
Ensembl chr 5:137,251,659...137,272,933
|
|
G |
Rtl3 |
retrotransposon Gag like 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RTL3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:71,947,343...71,951,008
Ensembl chr X:71,948,253...71,950,121
|
|
G |
Rtn2 |
reticulon 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RTN2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:78,935,056...78,948,069
Ensembl chr 1:78,935,104...78,948,069
|
|
G |
Runx1t1 |
RUNX1 partner transcriptional co-repressor 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RUNX1T1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:27,187,674...27,338,070
Ensembl chr 5:27,187,551...27,335,592
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
pioglitazone results in increased activity of [PPARA protein binds to RXRA protein]; pioglitazone results in increased activity of [PPARD protein binds to RXRA protein]; pioglitazone results in increased activity of [PPARG protein alternative form binds to RXRA protein] |
CTD |
PMID:11779144 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RYR1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions increases expression decreases expression |
ISO |
[pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA pioglitazone results in increased expression of S100A8 mRNA Pioglitazone results in decreased expression of S100A8 mRNA |
CTD |
PMID:28138970 PMID:28263783 PMID:30031879 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions increases expression |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of S100A9 mRNA; [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA pioglitazone results in increased expression of S100A9 mRNA |
CTD |
PMID:27935865 PMID:28138970 PMID:28263783 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sbk2 |
SH3 domain binding kinase family, member 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SBK2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:68,874,081...68,881,918
Ensembl chr 1:68,874,152...68,881,916
|
|
G |
Sbk3 |
SH3 domain binding kinase family, member 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SBK3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:68,867,847...68,873,249
Ensembl chr 1:68,868,238...68,871,392
|
|
G |
Sbspon |
somatomedin B and thrombospondin, type 1 domain containing |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SBSPON mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:3,402,763...3,433,338
Ensembl chr 5:3,402,648...3,435,420
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
ISO |
pioglitazone results in decreased expression of SCARB1 mRNA |
CTD |
PMID:20503262 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
Pioglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scgb3a2 |
secretoglobin, family 3A, member 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SCGB3A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr18:35,932,840...35,935,762
Ensembl chr18:35,932,840...35,935,762
|
|
G |
Scn2a |
sodium voltage-gated channel alpha subunit 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SCN2A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:50,302,781...50,437,504
Ensembl chr 3:50,302,877...50,437,214
|
|
G |
Scn4a |
sodium voltage-gated channel alpha subunit 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SCN4A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:91,246,936...91,296,670
Ensembl chr10:91,246,936...91,296,545
|
|
G |
Scn4b |
sodium voltage-gated channel beta subunit 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SCN4B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:45,446,580...45,462,294
Ensembl chr 8:45,446,215...45,462,292
|
|
G |
Scn7a |
sodium voltage-gated channel alpha subunit 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SCN7A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:51,335,841...51,438,308
Ensembl chr 3:51,335,841...51,438,256
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions increases expression |
ISO |
pioglitazone promotes the reaction [PPARG protein binds to SCNN1G intron] pioglitazone results in increased expression of SCNN1G mRNA |
CTD |
PMID:16007095 |
|
NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816
|
|
G |
Scube1 |
signal peptide, CUB domain and EGF like domain containing 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SCUBE1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:114,759,016...114,880,995
Ensembl chr 7:114,759,010...114,880,940
|
|
G |
Sec31b |
SEC31 homolog B, COPII coat complex component |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SEC31B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:243,376,283...243,404,557
Ensembl chr 1:243,378,456...243,404,557
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SELE mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selp |
selectin P |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SELP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions increases expression |
EXP ISO |
pioglitazone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of SERPINE1 mRNA] pioglitazone results in increased expression of SERPINE1 mRNA |
CTD |
PMID:16598202 PMID:21757225 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SFRP2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Sfrp4 |
secreted frizzled-related protein 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SFRP4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736
|
|
G |
Sftpa1 |
surfactant protein A1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SFTPA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685
|
|
G |
Sgca |
sarcoglycan, alpha |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SGCA mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:79,904,698...79,922,808
Ensembl chr10:79,908,738...79,922,813
|
|
G |
Sgce |
sarcoglycan, epsilon |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SGCE mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:32,771,477...32,842,238
Ensembl chr 4:32,771,477...32,842,254
|
|
G |
Sgcg |
sarcoglycan, gamma |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SGCG mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:35,388,836...35,435,072
Ensembl chr15:35,386,534...35,435,148
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of SGK1 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sh2d5 |
SH2 domain containing 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SH2D5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:150,469,738...150,480,615
Ensembl chr 5:150,467,728...150,479,955
|
|
G |
Sh2d7 |
SH2 domain containing 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SH2D7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:54,918,399...54,930,129
Ensembl chr 8:54,918,406...54,929,726
|
|
G |
She |
Src homology 2 domain containing E |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SHE mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:175,262,431...175,287,807
Ensembl chr 2:175,262,442...175,286,669
|
|
G |
Slc17a8 |
solute carrier family 17 member 8 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC17A8 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:23,994,212...24,049,498
Ensembl chr 7:23,994,217...24,048,079
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc25a24 |
solute carrier family 25 member 24 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of SLC25A24 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 2:196,761,076...196,799,236
Ensembl chr 2:196,761,274...196,799,231
|
|
G |
Slc25a34 |
solute carrier family 25, member 34 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC25A34 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:153,932,081...153,936,854
|
|
G |
Slc25a53 |
solute carrier family 25, member 53 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC25A53 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:100,306,917...100,319,662
Ensembl chr X:100,306,915...100,319,863
|
|
G |
Slc26a7 |
solute carrier family 26 member 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC26A7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:27,884,400...28,021,865
Ensembl chr 5:27,887,042...28,021,658
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
increases expression |
ISO |
pioglitazone results in increased expression of SLC27A1 mRNA |
CTD |
PMID:20723549 |
|
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of SLC2A3 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of SLC2A4 mRNA] |
CTD |
PMID:27350165 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions decreases expression |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC2A5 mRNA Pioglitazone results in decreased expression of SLC2A5 mRNA |
CTD |
PMID:27935865 PMID:30031879 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SLC2A6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
|
|
G |
Slc38a5 |
solute carrier family 38, member 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC38A5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:14,213,727...14,222,498
Ensembl chr X:14,213,729...14,222,498
|
|
G |
Slc4a5 |
solute carrier family 4 member 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC4A5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:115,710,101...115,810,330
Ensembl chr 4:115,725,592...115,810,323
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SLC6A12 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750
|
|
G |
Slc6a15 |
solute carrier family 6 member 15 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC6A15 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:38,553,055...38,607,239
Ensembl chr 7:38,553,196...38,607,239
|
|
G |
Slc6a17 |
solute carrier family 6 member 17 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLC6A17 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:195,107,434...195,155,697
Ensembl chr 2:195,107,438...195,155,697
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Pioglitazone results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
pioglitazone affects the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:23121773 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Pioglitazone affects the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:23121773 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLCO4C1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715
|
|
G |
Slco5a1 |
solute carrier organic anion transporter family, member 5A1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLCO5A1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:6,228,938...6,358,124
Ensembl chr 5:6,228,973...6,352,913
|
|
G |
Slit1 |
slit guidance ligand 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SLIT1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:240,409,559...240,558,127
Ensembl chr 1:240,409,561...240,558,127
|
|
G |
Sln |
sarcolipin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SLN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:54,221,389...54,248,110
Ensembl chr 8:54,243,542...54,247,791
|
|
G |
Sltm |
SAFB-like, transcription modulator |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of SLTM mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 8:71,215,995...71,261,821
Ensembl chr 8:71,216,612...71,261,825
|
|
G |
Smad9 |
SMAD family member 9 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SMAD9 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:138,956,326...139,006,315
Ensembl chr 2:138,986,471...139,006,307
|
|
G |
Smim10l2a |
small integral membrane protein 10 like 2A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of SMIM10L2A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:134,151,325...134,154,647
|
|
G |
Smoc1 |
SPARC related modular calcium binding 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SMOC1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 6:100,701,330...100,897,441
Ensembl chr 6:100,701,346...100,862,699
|
|
G |
Smpx |
small muscle protein, X-linked |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SMPX mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:37,233,209...37,292,266
Ensembl chr X:37,234,294...37,276,708
|
|
G |
Smtnl1 |
smoothelin-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SMTNL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:69,889,010...69,901,096
Ensembl chr 3:69,889,010...69,901,079
|
|
G |
Sncaip |
synuclein, alpha interacting protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SNCAIP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr18:46,205,846...46,343,932
Ensembl chr18:46,207,152...46,343,929
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression multiple interactions |
ISO |
pioglitazone results in increased expression of SOD1 mRNA; pioglitazone results in increased expression of SOD1 protein pioglitazone inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in decreased expression of SOD1 mRNA] |
CTD |
PMID:11172467 PMID:18513333 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects activity |
ISO |
pioglitazone affects the activity of SOD2 protein |
CTD |
PMID:21962020 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sorcs1 |
sortilin-related VPS10 domain containing receptor 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SORCS1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:249,080,662...249,594,520
Ensembl chr 1:249,081,355...249,594,507
|
|
G |
Sowahc |
sosondowah ankyrin repeat domain family member C |
increases expression |
ISO |
Pioglitazone results in increased expression of SOWAHC mRNA |
CTD |
PMID:30031879 |
|
NCBI chr20:27,195,198...27,199,664
Ensembl chr20:27,193,743...27,265,018 Ensembl chr20:27,193,743...27,265,018
|
|
G |
Sox10 |
SRY-box transcription factor 10 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SOX10 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544
|
|
G |
Sox8 |
SRY-box transcription factor 8 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SOX8 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA] |
CTD |
PMID:32473317 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sparcl1 |
SPARC like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SPARCL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:5,632,816...5,663,866
Ensembl chr14:5,632,569...5,663,865
|
|
G |
Speg |
striated muscle enriched protein kinase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SPEG mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:76,865,714...76,923,170
Ensembl chr 9:76,865,754...76,923,144
|
|
G |
Spink9 |
serine peptidase inhibitor, Kazal type 9 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SPINK12 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr18:36,427,043...36,430,271
Ensembl chr18:36,426,989...36,430,271
|
|
G |
Spocd1 |
SPOC domain containing 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of SPOCD1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 5:142,288,822...142,297,113
|
|
G |
Spon1 |
spondin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SPON1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:167,929,049...168,228,239
Ensembl chr 1:167,928,972...168,228,226
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [Streptozocin results in increased expression of SPP1 mRNA]; pioglitazone inhibits the reaction [Streptozocin results in increased expression of SPP1 protein] |
CTD |
PMID:16979161 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sprr1b |
small proline-rich protein 1B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SPRR1B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567
|
|
G |
Sprr2a |
small proline rich protein 2A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in increased expression of SPRR2H mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:177,815,964...177,816,236
Ensembl chr 2:177,815,964...177,816,236
|
|
G |
Sprr2b |
small proline rich protein 2B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in increased expression of SPRR2B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:177,852,824...177,853,096
Ensembl chr 2:177,852,824...177,853,096
|
|
G |
Sprr2d |
small proline-rich protein 2D |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SPRR2D mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:177,870,082...177,870,679
Ensembl chr 2:177,870,434...177,870,679
|
|
G |
Sprr2f |
small proline rich protein 2F |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SPRR2F mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:177,989,974...177,990,204
Ensembl chr 2:177,989,974...177,990,204
|
|
G |
Srl |
sarcalumenin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SRL mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:11,033,976...11,078,103
Ensembl chr10:11,034,035...11,078,101
|
|
G |
Srpx |
sushi-repeat-containing protein, X-linked |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SRPX mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:12,676,984...12,751,296
Ensembl chr X:12,566,645...12,747,882
|
|
G |
St3gal1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ST3GAL1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ST3GAL1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236
|
|
G |
Stac3 |
SH3 and cysteine rich domain 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of STAC3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:63,343,078...63,350,590
Ensembl chr 7:63,343,186...63,350,589
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases expression |
ISO |
Pioglitazone results in increased expression of STK11 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Stx1b |
syntaxin 1B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of STX1B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:182,415,544...182,434,385
Ensembl chr 1:182,415,546...182,441,280
|
|
G |
Styxl2 |
serine/threonine/tyrosine interacting like 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of STYXL2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:78,349,361...78,378,480
Ensembl chr13:78,349,365...78,378,458
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of SULT1C2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Sult1c3 |
sulfotransferase family 1C member 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SULT1C1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:7,221,580...7,266,991
Ensembl chr 9:7,221,578...7,267,030
|
|
G |
Susd5 |
sushi domain containing 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SUSD5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:113,996,771...114,036,133
Ensembl chr 8:113,997,362...114,035,861
|
|
G |
Svep1 |
sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SVEP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:72,811,200...72,988,185
Ensembl chr 5:72,811,410...72,988,525
|
|
G |
Svopl |
SVOP like |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SVOPL mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:66,697,550...66,751,699
Ensembl chr 4:66,698,177...66,758,978
|
|
G |
Syn1 |
synapsin I |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of SYN1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Syn2 |
synapsin II |
multiple interactions |
ISO |
Pioglitazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SYN2 protein] |
CTD |
PMID:32735850 |
|
NCBI chr 4:148,178,846...148,347,010
Ensembl chr 4:148,186,270...148,344,192
|
|
G |
Synpo2 |
synaptopodin 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SYNPO2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:211,217,099...211,371,267
Ensembl chr 2:211,216,783...211,371,267
|
|
G |
Sypl2 |
synaptophysin-like 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SYPL2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:195,849,062...195,863,794
Ensembl chr 2:195,849,062...195,863,794
|
|
G |
Tagln |
transgelin |
multiple interactions decreases expression |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TAGLN mRNA Pioglitazone results in decreased expression of TAGLN mRNA |
CTD |
PMID:27935865 PMID:30031879 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tarm1 |
T cell-interacting, activating receptor on myeloid cells 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of TARM1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:65,666,742...65,682,402
Ensembl chr 1:65,671,902...65,679,626
|
|
G |
Tas2r108 |
taste receptor, type 2, member 108 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TAS2R108 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:69,287,667...69,288,581
Ensembl chr 4:69,287,667...69,288,581
|
|
G |
Tbx15 |
T-box transcription factor 15 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TBX15 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:186,576,650...186,687,748
Ensembl chr 2:186,576,676...186,687,663
|
|
G |
Tbx4 |
T-box transcription factor 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TBX4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:70,730,686...70,760,829
Ensembl chr10:70,731,163...70,760,825
|
|
G |
Tcap |
titin-cap |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TCAP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:83,381,719...83,382,887
Ensembl chr10:83,381,719...83,382,887
|
|
G |
Tceal7 |
transcription elongation factor A like 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TCEAL7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:99,228,405...99,230,551
Ensembl chr X:99,228,458...99,230,543
|
|
G |
Tdh |
L-threonine dehydrogenase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of TDH mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:37,739,823...37,753,365
Ensembl chr15:37,739,823...37,753,365
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TDO2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Telo2 |
telomere maintenance 2 |
increases expression multiple interactions |
ISO |
Pioglitazone results in increased expression of TELO2 mRNA [Metformin co-treated with Pioglitazone] results in increased expression of TELO2 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr10:14,120,491...14,135,729
Ensembl chr10:14,120,818...14,135,698
|
|
G |
Tet1 |
tet methylcytosine dioxygenase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TET1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
ISO |
pioglitazone results in decreased expression of TFAM mRNA |
CTD |
PMID:20860658 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tff2 |
trefoil factor 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TFF2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:9,215,750...9,219,619
Ensembl chr20:9,215,761...9,219,619
|
|
G |
Tg |
thyroglobulin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of TG mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression |
ISO EXP |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of TGFB1 protein] pioglitazone results in decreased expression of TGFB1 mRNA pioglitazone affects the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; pioglitazone inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; pioglitazone inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA] Pioglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:12055599 PMID:16484506 PMID:16611854 PMID:17015710 PMID:32613381 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgm7 |
transglutaminase 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of TGM7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:108,051,890...108,068,116
Ensembl chr 3:108,051,890...108,076,239
|
|
G |
Thbs1 |
thrombospondin 1 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [Streptozocin results in increased expression of THBS1 mRNA]; pioglitazone inhibits the reaction [Streptozocin results in increased expression of THBS1 protein] |
CTD |
PMID:17063547 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of THRSP mRNA |
CTD |
| |